Mycobacterium tuberculosis (Mtb) is an extraordinarily successful human pathogen, one of the major causes of death by infectious disease worldwide. A key issue for the study of tuberculosis is to understand why individuals infected with Mtb experience different clinical outcomes. To better understand the dynamics of Mtb infection and immunity, we coupled nonhuman primate experiments with a mathematical model we previously developed that qualitatively and quantitatively captures important processes of cellular priming and activation. These processes occur between the lung and the nearest draining lymph node where the key cells mediating this process are the dendritic cells (DC). The nonhuman primate experiments consist of bacteria and cell numbers from tissues of 17 adult cynomolgus macaques (Macaca fascicularis) that were infected with Mtb strain Erdman (ϳ25 CFU/animal via bronchoscope). The main result of this work is that delays in either DC migration to the draining lymph node or T cell trafficking to the site of infection can alter the outcome of Mtb infection, defining progression to primary disease or latent infection and reactivated tuberculosis. Our results also support the idea that the development of a new generation of treatment against Mtb should optimally elicit a fast DC turnover at the site of infection, as well as strong activation of DCs for maximal Ag presentation and production of key cytokines. This will induce the most protective T cell response.
O ne of the major causes of death by infectious disease worldwide is Mycobacterium tuberculosis (Mtb)
3 infection. Despite the fact that one-third of the world population is infected with Mtb, the majority of infected individuals experience an asymptomatic state known as latency, with only 5-10% progressing to active disease or primary tuberculosis (TB). How and why some individuals remain in a latent state while others progress to primary disease or reactivation are still unclear.
Mtb primary infection progression may have a slow time course with reactivation being an even longer process, up to 33 years (1, 2) . When active TB develops in humans, infection localization, severity, and outcome are highly variable, and little data exist regarding infection kinetics. A positive purified protein derivative test status indicates infection, and progression from negative to positive purified protein derivative test signifies progression from exposure to infection. Due to the wide time range over which infection can progress to an active state, the time frame for primary disease to manifest ranges from 1 to 5 years (3) (4) (5) (6) . This represents the time frame within which patients who have been exposed to Mtb likely progress to a state of clinical disease. Individuals exposed to the bacilli who do not progress to active disease are generally believed to contain dormant bacilli; this state is often referred to as latent TB (7) .
During infection, macrophages (Ms) are the prime target cells for Mtb, which after their activation can both kill intracellular bacteria and participate in a protective Th cell type 1 (Th1) response. As professional APCs, dendritic cells (DCs) play a major role in establishing an effective adaptive response. In fact, there is growing evidence that generation of different types of immune responses is controlled by DCs (8, 9) . A novel hypothesis suggests that different DC lineages drive the final commitment of T cells (8, 10 -21) . However, other evidence suggests that the same subset of DCs can promote either a Th1 or a Th2 response (8) . This indicates that DC subsets can induce different Th responses according to a combination of signals. Activation signals can affect the capability of DCs to prime and induce potentially different Th responses. These include the nature (22) and load of microorganism (23) , factors released by tissue and inflammatory cells (damage signals) (24 -28) , physical interactions with other cell types (29) , death of infected cells (30) , duration of the TCR engagement (8) , and pattern recognition receptors (31) (32) (33) .
DCs and Mtb
Although the role of Ms in Mtb infection has been extensively addressed (34) , more recent studies (35) (36) (37) (38) (39) (40) have focused on the interaction of Mtb with DCs. Elaborating population dynamics of DCs in vivo can help define the role of these cells during Mtb infection. DCs generated from progenitors in the bone marrow migrate into peripheral tissues through the bloodstream. Immature or resting DCs (IDC) are present in high numbers at sites of infection (such as the lung) at the onset of the inflammatory response (41) (42) (43) (44) (45) (46) (47) (48) (49) , and they are specialized for Ag uptake and processing (35, 39, 46 -48, 50, 51) . After bacterial uptake, DCs change their behavior, as observed both in vitro and in vivo (48) , reducing their phagocytic and/or endocytic capability and initiating expression of immune stimulatory molecules (maturation). DC maturation is initiated in nonlymphoid tissues where DCs take up Ag and continues within secondary lymphoid tissues, in particular, the draining lymph node (DLN). Differentiation of IDCs in the DLN leads to a phenotypic change into the mature phenotype (mature DC (MDC)).
Migration (and presumably maturation) of DC from nonlymphoid tissues into DLN is promoted by locally produced inflammatory cytokines and other agents that are generated during local infection or trauma (26, 27, 52) . Infection indeed has an effect on homeostatic chemokine expression in the lung (53) and on DC localization into secondary lymphoid tissues by altering expression of chemokines and chemokine receptors (e.g., CCR7 and CCR6) (54) . These signals drive DC trafficking and migration first to the lymphatic vessels and then to DLNs via CCL21/6Ckine and other chemokines (e.g., MIP-3␤ or CCL19, CCL21/6Ckine, CCL20/ MIP-3␣) released by MDCs in the DLNs (53, 55) . IDCs that take up bacteria also express high levels of adhesion molecules (47, 49, 56, 57) that allow migration into DLNs.
Once in the DLN, DCs (MDCs) display a mature phenotype resulting in expression of high levels of long-lived MHC I and MHC II molecules (10, 34, 35, 37, 39) (from 5-to 20-fold over IDCs) that enable more stable presentation of Ag (46) . Other molecules that are expressed after maturation are costimulatory molecules including B7 (up to 100-fold) (10, 46) , CD40, and Fas (27) . Moreover, MDCs produce and enhance expression of CCL18 (pulmonary and activation-regulated chemokine/DC-CK1), a chemokine that specifically attracts naive T cells to DLNs (57) (58) (59) . The maturation-migration process of DCs is enhanced during Mtb infection, whereas infected Ms show little phenotypic change (34, 35, 39, 60) .
Before infection, resting Ms and IDCs do not produce significant amounts of cytokines (35, 39) . Recent studies highlight how, after Mtb infection, MDCs release Th1-inducing cytokine IL-12 in very high amounts (35, 39, 49) . On the contrary, infected Ms produce mainly anti-and proinflammatory cytokines (e.g., IL-10, TNF-␣) (35, 37, 39) ; thus, during Mtb infection, Ms and DCs likely perform different functions. Because MDCs are known to migrate to the DLN for presentation to naive T cells and because they produce IL-12 in a great amount after Mtb uptake, it seems likely that a Th1-type environment is established in the DLN early in the infection process (61, 62) . The cytokine environment (e.g., GM-CSF, IL-10, and IL-4) may also play a role in monocyte maturation into either DCs or Ms (63) , defining cell population phenotypes at the site of infection (64) .
To study the dynamics outlined above, we have applied a mathematical model of Mtb infection previously published by our group (65) to determine mechanisms controlling infection outcome. We developed a two-compartment model that qualitatively and quantitatively captures important processes of cellular activation and priming as well as relevant migration patterns between DLN and lung. To guide our work, a nonhuman primate (NHP) model of TB is studied concurrently for data comparison (66, 67) . This NHP model has provided data for parameter estimation as well as data for validation of our virtual experiments. Because this study is focused on studying human TB, we must rely on human bronchoalveolar lavage (BAL) fluid and cells as a surrogate marker of immune dynamics in lung. In actuality, the immune response to Mtb occurs in tissue via the development of granulomas. We explore this granuloma response in other work (J. L. Segovia-Juarez, S. Ganguli, and D. E. Kirschner, manuscript in preparation; Ref. 68). 4 Our main goal here is to address the relevance of trafficking of DCs to and from the DLN in establishing a protective immune response against Mtb. We also compare our virtual human experiments of different infection outcomes in humans during Mtb infection with our NHP experimental data, suggest new experiments, and finally define potential treatment strategies.
Materials and Methods

NHP model
Seventeen adult, simian retrovirus type D-negative cynomolgus macaques (Macaca fascicularis) (6-9 years of age; 3.1-9.7 kg) were infected with Mtb strain Erdman, ϳ25 CFU/animal, via bronchoscope into the right middle or lower lung (67) . All animals were individually housed in 4.3-square foot stainless-steel cages equipped with lexan fronts to reduce the potential for aerosol contact between animals. All cages were maintained within a negatively pressurized BioBubble (Colorado Clean Room Company, Fort Collins, CO) located within a biosafety level 3 suite. All animal experimentation guidelines were followed in these studies, and the University of Pittsburgh School of Medicine Institutional Animal Care and Use Committee approved all experimental manipulations and protocols.
BAL was performed monthly (67) . Monkeys were euthanized and necropsied either at a predetermined time postinfection or if they developed a rapidly progressing TB. At necropsy, tissue pieces from lung, lymph node, and visible granulomas were placed into sterile RPMI 1640 medium in preweighted tubes, and weight of the tissue was recorded. Tissue was homogenized to obtain single-cell suspensions in a MediMixer (BD Biosciences, San Jose, CA). Ten-fold dilutions of these homogenates, as well as BAL fluid, were plated on 7H10 agar plates (Difco, Detroit, MI), incubated at 37°C and 5% CO 2 , and CFU were counted after 4 wk. Cell numbers were determined by trypan blue exclusion in single-cell suspensions from tissues. Flow cytometry was performed on lung, granuloma, and lymph node cell preparations at necropsy to determine the composition of the tissues, as previously described (67, 69) . Abs used were anti-CD3 (clone SP34), anti-CD14 (clone MOP9), anti-CD4 (clone SK3), antiCD11b (clone ICRF44), anti-CD16 (clone 3G8), anti-CD8 (clone SK1), and anti-HLA-DR (clone TU36), all from BD Biosciences (Mountain View, CA).
Staining and quantitation of fascin-positive cells
Immunohistochemical staining of 14-m tissue sections was performed using anti-fascin (also known as p55) murine mAb (clone 55K-2; DakoCytomation, Carpinteria, CA). Tissue sections from cynomolgus macaques infected with Mtb were pretreated by microwaving for a total of 10 min in 0.01 M sodium citrate (pH 6.0), followed by application of the primary Ab (diluted 1/100 in PBS) for 1 h in a humid chamber at room temperature. Primary Ab was detected with the PicTure-Plus detection system (Zymed Laboratories, San Francisco, CA) using 3,3Ј-diaminobenzidine as the final substrate. The granuloma size (surface area in square micrometers) and the percentage of fascin-positive cells were quantitated in image capture through an RT Slider Spot camera (Diagnostic Instruments, Sterling Heights, MI) using the MetaView imaging software package (Universal Imaging, Downington, PA). Images of granulomas were acquired through a ϫ4 objective lens on a Nikon (Melville, NY) E600 research microscope, and the total and nonnecrotic surface areas of the granulomas were measured. Five random images of the cellular portion of each granuloma were captured through a ϫ60 objective lens, and the total numbers of cells (nuclei) and the numbers of fascin-positive cells were manually counted in each image.
Mathematical model
We study DLN dynamics and compare them with those occurring in the infected lung using an existing mathematical model of the host response to Mtb (65) . This model comprises two relevant physiological compartments (the lung and the DLN) and 17 variables: 13 in the lung and 4 in the DLN. The variables in the lung are as follows: Ms (resting, activated, and infected), immature or resident DCs, bacteria (both extracellular and intracellular), cytokines (IFN-␥, IL-12, IL-4, and IL-10) and lymphocytes (Th precursor (Th P ), Th1, and Th2). In the DLN compartment, we track MDCs, lymphocytes (naive T cells (T) and Th P (Th P LN )), and IL-12. The model formulation and testing is discussed in detail in Ref. 65 ; however, we briefly outline key interactions included. Fig. 1 (9, 70 -72) . Although they can be stimulated to produce both Th1-type and Th2-type cytokines, Th1 and Th2 cells are likely already committed. The existence of Th P is controversial, and indeed this class may encompass a spectrum of cells differentiating from naive to Th1/Th2 phenotypes, as well as memory T cells (9, 62) .
Our main hypothesis regarding lymphocyte populations is that the primary cellular output from DLNs is mainly of Th P type. These cells are then modulated by the local cytokine environment on the way to, and at the site of, infection (26, 27, 64) . These cells could also remain in a Th P state or become memory T cells (however, we do not address memory T cell dynamics in the present model).
Although we do not explicitly account for effector CD8 ϩ T cells (CTLs) in this model, we account for their effects in two key ways. First, we include an extra source of IFN-␥, assumed to come directly from CTLs (73) (74) (75) , and second, we account for CTL-induced killing of infected Ms beyond what is accomplished via Th1 apoptosis. To this end, we assume the action of CTLs is proportional to Th1-effector function (targeting intracellular bacteria); thus, the E:T ratio (Th1/M I ) indirectly determines the rate of infected M killing. T cell killing of infected Ms by apoptosis and cytotoxic action is accomplished via the rate k 14 , and our results indicate that it is crucial in determining infection outcome (65) . In other work, we explore the role of CTLs in Mtb infection in a more mechanistic fashion (D. Sud, J. L. Flynn, and D. Kirschner, manuscript in preparation).
For the purpose of this work, we briefly review the virtual latent infection and active TB scenarios and compare them to our NHP experimental data. We also use the mathematical model to perform virtual deletion and depletion experiments and discuss the sets of rates/rate constants that are responsible for leading to different infection outcomes (namely, latency, clearance, active disease, and reactivation). It is the host-pathogen processes governed by these rates/rate constants that are likely targets for further experimental studies. As discussed in Ref. 65 , we consider the total bacterial load as the most informative marker of infection progression in our simulations.
Uncertainty and sensitivity analysis of rates/rate constants
Each different cell-cell and cell-cytokine interaction is represented in the model by mechanistic terms with specific rates/rate constants. The effect of a particular term within the system is studied by varying the respective parameter. For example, to study the effect of Ag presentation in the DLN performed by MDC, we vary the parameter accounting for that mechanism in the model over a given biologically relevant range. Setting that parameter to zero (or to very low levels) signifies ineffective or no Ag presentation in the DLN. To systematically study the complex network of interactions, the model parameter space has been fully explored to assess how variations in a single parameter (individual effect) or which combination of parameters (multiple effect) might discriminate between different infection outcomes.
To quantify the importance of each mechanism, all effects are evaluated using statistical techniques called uncertainty and sensitivity analyses. They are implemented in C code and based on Latin hypercube sampling and partial rank correlation (PRC), respectively (76 -79) . The Latin hypercube sampling method explores effects of uncertainties in our parameter estimation on model outcomes and allows for simultaneous random, evenly distributed sampling of each parameter within a defined range. The correlation between parameter variation and a specific variable outcome (for example, how Ag presentation in the DLN correlates with total bacterial load) is then computed by combining the uncertainty analyses with PRC. PRC coefficients tell us the nature and degree of sensitivity between different mechanisms within the model, and help us to identify and quantify the mechanisms that are critical to affecting the outcome when varied.
Virtual deletion and depletion experiments
One of the main advantages of a mathematical model is the ability to manipulate the equations to ask questions about interactions and rates within the system. For example, we can easily perform both virtual deletion and depletion experiments and compare the results with known experimental data in mice as well as perform new experiments that may be difficult or presently impossible to perform (for example, DC and Th1 virtual deletion and depletion experiments).
Virtual deletion experiments mimic knockout (disruption) experiments, removing an element from the system from the beginning of the simulation, before the bacteria enter the host. This analysis guides our understanding as to which elements may be relevant in controlling initial infection and establishing latency. We can also simulate depletion experiments, for example, after the system has achieved latency, by setting to zero the parameter related to cytokine production (mimic Ab-neutralizing effects). This allows us to determine what elements control maintenance of the latent state.
Results
Measure units: scaling lung and lymph node compartments
Our system is developed to model human TB, both at the site of infection and in the DLN. Most human experimental data in the lung come from BAL cellular and fluid samples (80 -82) . BAL measurements as a surrogate of events in the lungs have some drawbacks. For example, they overestimate M population size and activity (i.e., cytokine production) in the lower respiratory tract, underestimating DC and lymphocyte populations. Certainly BAL samples are not informative regarding the DLN.
To scale lung and lymph node compartment cell trafficking, we use volumetric measure units. Table I illustrates data on the average cell recovery from tissue of Mtb-infected NHPs at necropsy. A reasonable upper bound of hilar lymph node volume might be the volume of perihepatic lymph node, within the order of 3.4 Ϯ 2.4 ml (83), where 1 ml ϭ 1 cm 3 . Based on visual experience of our NHP necropsies, a more reasonable upper limit for hilar lymph node is probably 1 cm 3 (sometimes even smaller). Total cells recovered from the hilar lymph node of Mtb-infected NHPs at necropsy is on the order of 10 7 (Table I) , approximately on the order of the number of cells recovered in a cubic centimeter of the lung lobes (and also on the order of total BAL recovery). Variability in cell numbers recovered from lung tissue is due in part to differences in disease status, NHP anatomy, and perfusion at necropsy.
We can reasonably use cells per cubic centimeter as our cell population measure unit (both in the lung and in the lymph node). We assume there exists an average initial cell population of 10 4 in the hilar lymph node and 10 6 cells in 1 cm 3 of the lung (initially, there are fewer cells in the lung when there is no infection, and thus no inflammation is present). We also calibrate initial conditions of our virtual infection model to match a hypothetical cell distribution in the two compartments of lung and DLN (see Ref. 65) . The initial bacterial inoculum is 25 bacteria (derived from the NHP experiment protocol). Each equation of the model thus represents the incremental variation of a certain quantity over time (day): picograms per milliliter (ϫ10 6 cells) for cytokine concentrations, and cells per cubic centimeter of tissue for cellular variables.
Review of the latency scenario
Because our goal is to use the mathematical model to determine which factors are crucial in establishing and maintaining latency, we briefly review the latency scenario obtained with our model simulations (further details about this and other virtual experiments, such as primary TB, can be found in Ref. 65 ). We defined two bacterial subpopulations: intracellular and extracellular bacteria. Intracellular bacteria are those that have been internalized by resting Ms and IDCs, whereas all other bacteria are considered extracellular. These simulations were basically generated with the rate/rate constants used in Ref. 65 . We change only a few parameters to obtain more realistic bacterial population numbers.
Initial stages of latency are similar to primary TB up to day 250 (see Ref. 65) . A sustained M activation (see Fig. 2 ) coupled with a more efficient cell-mediated response result in lower levels of intracellular bacteria (at ϳ4 ϫ 10 3 cells/cm 3 ; see Fig. 3 ). The number of infected Ms is small, and total bacterial load is represented by intracellular bacteria housed within infected Ms (extracellular bacterial load is almost zero; see Fig. 3 ). The few extracellular bacteria are readily internalized by both Ms and IDCs and are also taken up by activated Ms, thus containing infection. Bacteria are completely controlled, and latency is achieved by ϳ200 days. Overall, there is a 60% increase in healthy resting Ms in the lung.
Cytokine levels (Fig. 3) are predominantly of type 1 and are sustained after latency has been achieved. Our model simulations reflect the order of magnitude found in BAL samples and qualitatively represent the cytokine environment at the site of infection (84 -86) . IL-10 adequately counterregulates IFN-␥ and IL-12 activity, down-regulating M activation. These cytokines reach a stable level, with IFN-␥ 2-fold higher (1.4 ϫ 10 2 pg/ml) than IL-12. As expected, IL-4 levels are much lower than those of IFN-␥ and IL-12 (87) .
A protective Th1 cellular response is mounted after 200 days, with Th1 cells peaking at around 4 ϫ 10 3 cells/cm 3 after 1 year, and then decreasing to very low levels once latency has been established (Fig. 4) . Although very low, these levels are crucial to maintaining latency (as is confirmed by virtual depletion experiments; see Virtual depletion experiments). After 200 days, Th P cells in the DLN (Fig. 4) decrease (10-to 15-fold lower than primary TB, see Ref. 65 ), whereas Th P in the lung continue increasing and remain higher than those in the DLN, stabilizing much later than other cells in the system. This suggests that, during peak infection, a faster migration of Th P cells from the DLNs to the lung may be one explanation for the host to contain bacteria during latency. DC levels return to baseline after latency is achieved (Fig.  2) , suggesting how their role is necessary for both establishing (via MDC presentation in the DLN) and maintaining latency (with IDCs as sentinels for further extracellular bacteria invasion). Virtual deletion and depletion experiments confirm these findings (see below).
NHP data vs mathematical model simulations
We compared data collected from NHP experiments with our model results. To perform a correct comparison, we made some assumptions. Our measure unit is number of cells per gram (or cubic centimeter) of tissue in the lung or lymph node. The number of cells is likely to be different in a granuloma vs nearby nongranulomatous tissue, and this complicates our ability to compare directly, depending on from where the sample is taken. Our NHP data represent both granulomatous and nearby nongranulomatous tissue (monocyte and lymphocyte gates and CFU numbers). Table II shows data gated from monocyte gate (CD11b ϩ ) of Mtb-infected lung of six representative NHPs. These NHPs were sacrificed at different days postinfection (from 60 to 450 days), and each experienced a different infection outcome: from minimal infection with no symptoms (latency or chronic TB) to active TB (from moderate to advanced infection) (see Table I in Ref. 67 for details about monkey labels and stage of disease at necropsy for each monkey). Disease status determined the time of necropsy. BAL measures give larger intervals for cell numbers than lung lobe samples, confirming that BAL is more variable and in general not a robust measure.
The cell types in 1 g of lung tissue represented in our model are Ms, IDCs, and lymphocytes. They account for ϳ20 -40% of the total cell population in the lung (type 1 and type 2 pneumocytes, as well as endothelial cells represent a very high percentage). The cell types in 1 g of lymph node tissue represented in our mathematical model are MDCs and lymphocytes. They represent approximately between 10 and 20% of the total cell population in the lymph node (B cells, follicular DCs, and endothelial cells represent a very high percentage). To compare NHP data with our model simulations, we scaled our virtual experiment data according to the percentages given above, namely, model simulations represent 20 -40% and 10 -20% of the cell populations in the lung and lymph node, respectively. Table III shows our virtual experiments of M, DC, and lymphocyte population percentages in the lung and LN during latency and active TB at different days postinfection.
Our model simulations give M population percentages very similar to NHP data (both for latency and active TB). In fact, the M percentage predicted by our model during latency is between 18 and 38% (considering an interval of ϳ400 days, from 70 to 450 days postinfection; see Table III ) compared with an interval of 13-40% of the NHP data (see Table II , Lung lobes). We obtain similar values for active TB simulations (namely, between 14 and 38.4% within the same time frame; see Table III ). These results are very similar to the 10 -30% interval suggested by the NHP data (Table II , Lung lobes). Our model also has the advantage to discriminate between different M subpopulations (resting, infected, and activated), giving additional information that could be tested in future experimental studies. 
Our model simulations are in line with NHP CD4
ϩ cell data in the lung during latent TB infection: they are both Ͻ1%. In contrast, our model simulations underestimate lymphocyte number in the lymph node. NHP data of CD4 ϩ cells in the lymph node samples are very high (comparing with the lung): ϳ36%, but with a large variation (SD, Ϯ14.11; see Table V) . Our model simulations give values between 3.2 and 19.6%. This is likely due to the fact that CD8
ϩ T cells, memory T cells, and many other T cell subpopulations are not presently represented in the lymph node compartment of our model and also that our virtual experiments only simulate the number of Mtb-specific Th cells.
Regarding DC population levels in the lung, Table VI gives a confidence interval (95%) of 5.46 -12.49% for the average percentage of p55 ϩ cells in two Mtb-infected NHPs (with active TB). We use this interval to approximate the number of granuloma cells that express a DC phenotype. Our model simulations (see Table  VI ) gives values for DCs in the lung (IDCs) between 1 and 3.6% in latency and 0.6 -10% in active TB (considering an interval of ϳ400 days, from days 70 to 450 postinfection). This slight underestimation is likely due to the way that measurements are performed in granulomatous tissues on NHPs. Our model includes only IDCs in the lung, and p55 could account for a MDC phenotype as well. However, these data suggest that both IDCs and MDCs may be present at the site of infection. (88) .
Considering the bacterial load, Table VII compares CFU data collected in 17 Mtb-infected NHPs (67) with our model simulations. Represented are three different infection progressions, namely, rapid TB (10 wk), active TB (from 4 mo up to 1 year), and latency (no sign of disease in the first 6 mo). Because data are expressed per gram of tissue, we assume that 1 cm 3 approximates 1 g of tissue (both in the lung and in the hilar lymph node). One subject experienced rapid TB, eight experienced active/chronic TB, and eight experienced latent TB. Two latently infected primates had reactivation, whereas one of the eight active/chronic TB cases resolved infection only after 1 year (see Table I in Ref. 67 for details about monkey labels and stage of disease at necropsy for each monkey).
We also assume that, during disease, CFUs in the lung are mostly represented by extracellular bacteria, because numbers are much larger than intracellular. CFUs in granuloma alone likely represent a good estimate of intracellular bacteria. To determine number of bacteria in the hilar lymph node, we hypothesize that each MDC has internalized up to 10 bacteria. Our model gives results that are in line with our NHP experiments. Latency is particularly interesting: it reflects the absence of extracellular bacteria in the lung and supports the idea that "good" granuloma formation could contain infection (all bacteria are intracellular or below the level of detection).
Virtual deletion experiments
We use our model to explore mechanisms behind both cell and cytokine dynamics. We study cytokines IFN-␥, IL-12, and IL-10, and we explore DC and CD4
ϩ T cells, all through virtual deletion experiments. IL-12 deletion is performed both at the site of infection and in the DLN. The advantage of our model is that we were able to perform virtual knockout experiments that are presently difficult or impossible to do experimentally (such as DC and Th1 deletion).
Our virtual IFN-␥ deletion (data not shown; see Ref. 65 ) shows a lack in M activation, with no Th P migration occurring into the lung due to the very low chemokine gradient present at the site of infection (produced by activated Ms). Without IFN-␥, they are unable to activate Ms, and an exponential growth in extracellular bacteria (100-fold higher than latency) occurs. This is confirmed in mouse and human infections (89 -92) where active TB results. Similar results occur for virtual IL-12 deletion (data not shown; see Ref. 65 ). IL-10 depletion supports the idea of a regulatory role for IL-10 (93, 94). Without IL-10, the system undergoes an abnormal increase in resident and activated Ms (data not shown; see Ref. 65) , likely leading to a large inflammatory response or increased risk of reactivation.
All of the figures to follow represent the immune response at the site of infection of lung (A) and in the DLN environment (B). They are both scaled to cells per cubic centimeter of tissue (except for cytokines that are measured in picograms per milliliter), but in panels A, we refer to BAL, and in panels B, to cells per gram of tissue. In general, panels A comprise four subplots describing M populations, cytokine concentrations, Th1 and Th2 cells, and bacterial subpopulations, respectively. Panels B illustrate DC dynamics, naive T cells, IL-12 in the DLN, and Th P trafficking. Although Th P LUNG and IDC belong to the lung compartment, they have been included in panels B to compare trafficking and migration patterns of DCs and Th P between the lung and the DLN.
We perform two virtual DC deletion experiments. In the first experiment, we halt recruitment of new IDCs to the site of infection and prevent IDC migration to the DLN (Fig. 5) . In the other experiment (data not shown), we set the IDC population in the lung to zero from the beginning and keep it zero ("complete" DC depletion). Both types of DC deletion experiments lead to an absence of T cell-mediated immunity (no Ag presentation occurs in the DLN), with an extracellular bacterial burst in Ͻ500 days (Fig. 5A) . The same scenario occurs when CD4 ϩ T cells are deleted using our model (data not shown), where a lack of T cell immunity is not compensated for by innate immunity (Ag uptake by IDC at the site of infection), and leads to an exponential increase of extracellular bacteria (data not shown; same as Fig. 5A ). We also explore virtual deletions of specific subsets of lymphocytes, namely, Th1 cells (data not shown). These results highlight how a protective Th1 immunity is necessary in establishing latency, and that a Th2 response is not protective (data not shown). 
Virtual depletion experiments
We use our model also to make predictions by performing a virtual depletion of different cytokines and cells (IFN-␥, IL-12, and IL-10), DC, CD4 ϩ T cells (MHC II), and Th1 cells, respectively. Depletions are performed after 1000 days (after the system achieves latency): infection outcome after depletion indicates what likely contributes to maintaining latency or inducing reactive disease.
In the latent model of infection, CD4 ϩ T cells, NO synthase, and TNF-␣ have been demonstrated to be necessary to maintain control of infection (3) . Depletion of IFN-␥ and IL-12 throws the system out of latency into active disease reactivation.
In fact, depletion of IFN-␥ and IL-12 causes a drastic decrease in both activated M and T cell populations, with extracellular bacteria increasing to uncontrollable levels that cannot be compensated for by DC trafficking and presentation (data not shown). This is in line with several CD4
ϩ deletion/depletion experimental data (3, (95) (96) (97) and confirms our virtual deletion simulation results.
We are able to perform two different virtual DC depletion that cannot be done experimentally. The first experiment is performed by setting to zero both IDC recruitment at the site of infection and IDC migration to the DLN (at 1000 days postinfection), thus eliminating any possibility of additional Ag presentation and T cell immunity (partial DC depletion). The other experiment sets the IDC population in the lung to zero ("complete" DC depletion), after 1000 days. Both DC depletion experiments lead to reactivation, but in the case of partial DC depletion experiment (Fig. 6) , there is an interesting trade-off between IDCs and extracellular bacteria: the longer it takes to deplete the IDC population at the site of infection (which depends on the IDC death rate, because we halted IDC recruitment), the higher the possibility of enhancing a second wave of effector T cell response at the site of infection (Fig. 6A, Effector Cell plots) . Because the resident IDC population will eventually deplete, progression to primary TB is just a matter of time. This also could induce reactivation or chronic infection scenarios. Because in our model we do not include memory T cells, the level of T cell immunity is determined by the level of priming of new T cells and T cell proliferation. Thus, CD4
ϩ T cell (MHC II) depletion is performed by depleting MDC presentation in the DLN (after 1000 days), and it leads to primary TB (data not shown, outcome similar to Th1 virtual depletion experiment of Fig. 7) . Again, using our virtual infection model, we are able to deplete a specific subset of lymphocytes, namely Th1 cells (it cannot currently be done experimentally). This result is in line with the CD4 and Th1 virtual deletion experiment (data not shown) and highlights how a protective Th1 immunity is necessary in maintaining latency, even though it may be very low, and the absence of this response leads to reactivation (Fig. 7A) .
Mechanisms leading to different infection outcomes
To determine which mechanisms in the model control whether the system progresses to latency or to active disease, we performed a detailed uncertainty and sensitivity analysis on all parameters in the system (see Materials and Methods) . Surprisingly, of the 50 interactions in the model, only a handful are determinative in infection outcome. In a previous study (65) , we showed the importance of infectivity and uptake/killing parameters in establishing and maintaining latency. To better understand the role of DCs in Mtb infection, we classify the mechanisms (based on the parameters that determine the terms) into three groups, namely, presentation/activation/differentiation, trafficking, and uptake/killing parameters (see Table VIII ). The importance of DCs in determining latency is supported by a key role for factors involved in Ag presentation. In fact, primary TB results if the level of MDC-T cell interaction in the T cell area of the DLN is decreased or if the MDC death rate is increased (that could be due to a faster MDC death rate or faster rate of "exhaustion" of MDCs in the DLN).
A key role for MDC activity in the DLN is also supported by the importance of the parameter regulating the production of IL-12 by MDCs. If this rate is decreased, primary TB occurs, and this is due to a lack of Th1 response. New data in a mouse model lacking CD40 support this finding (98) . However, if we decrease the two main DC trafficking parameters, namely, the maximal rate of migration of IDC to the DLN and the percentage of precursor Th cells migrating out of the DLN into the blood, fast progressive infection occurs. This is again a result of reduced adaptive immunity at the site of infection.
This suggests that a delay in DC and T cell trafficking can alter the outcome of Mtb infection. Moreover, the protective innate role of DCs as a reservoir for Mtb bacteria during latency is confirmed by the relevance of the parameter governing the normal turnover rate of IDCs at the site of infection: decreasing this rate results in a constant but continuous increase in bacterial load ("slow" infection or a possible reactivation scenario).
Discussion
In this study, we coupled a NHP model with a virtual infection model of the human immune response to Mtb (65) to examine the role of DC trafficking between the site of infection (lung) and the secondary lymphoid tissue (lymph node) in determining the infection outcome.
Our model simulations highlight the role of phagocytic cells (Ms and DCs) in initiating and directing adaptive T cell immunity, in particular, the key action of DCs in establishing and maintaining latency. DCs have multiple roles: they participate in innate immunity by internalizing bacteria at the site of infection and represent the main link between innate and adaptive immunity via trafficking from lung to lymph node.
The first stage of infection begins with inhalation of tubercle bacilli. Resident Ms and IDCs in the lung ingest bacilli and likely often clear them (via innate immunity). There are multiple mechanisms for the uptake of Mtb, involving a number of different host cell receptors (99) , and distinct routes of entry may lead to differences in signal transduction, immune activation, and intracellular survival. For example, the main Mtb receptors on Ms are complement receptor 3 and mannose receptor, whereas recent evidence suggests that DC-SIGN is a primary Mtb receptor on DCs (100). Virulent strains of Mtb are phagocytosed through the mannose receptor, whereas attenuated strains are not (101) , suggesting that a different route of entry might be advantageous to mycobacteria, and that DC-SIGN-mediated entry into DCs likely influences bacterial persistence and host immunity (100). In vivo, the possible role of these events in immune evasion by Mtb remains to be determined. Our model suggests how increasing the rate of bacterial uptake by resident IDCs could be advantageous both in terms of a stronger innate response and as a more efficient link to an effective adaptive response.
To validate our model simulations, Mtb-infected NHP have been studied. M and DC percentages resulting from our model simulations are very similar to the NHP experimental data. Moreover, CFU data are in line with our simulations, especially in latently infected NHPs, where the absence of Mtb in the lung of latently infected primates suggests that the total bacterial load is intracellular and contained within granulomas.
Our simulations indicate that DCs are necessary in establishing protective immunity and in containing infection. The main result of this work is that a delay either in DC migration to the DLN or T cell trafficking to the site of infection can alter the outcome of Mtb infection (see Table VII ) or define a progression from latency to active TB or a possible reactivation scenario. Delayed DC migration can be simulated in our model by decreasing IDC turnover rates or IDC migration rates from the site of infection to the DLN. T cell trafficking can be altered by decreasing the percentage of precursor Th cells migrating out of the DLN. We can also modulate the intensity and duration of Ag presentation in the DLN by changing MDC-naive T cell interaction term or MDC half-life, respectively. Our results are in line with the idea that a fast DC turnover at the site of infection, as well as strong activation of DCs leading to maximal Ag presentation and production of key cytokines (inducing the most protective T cell response), could represent a viable strategy for the development of a new generation of treatments against Mtb (35, (102) (103) (104) (105) (106) (107) .
